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Background
Synthesis of cGMP in cardiomyocytes is stimulated by
natriuretic peptides via GC-A signalling as well as nitric
oxide (NO) via soluble guanylyl cyclase (sGC).
Different studies in vitro/in vivo have demonstrated that
cGMP can inhibit myocardial hypertrophic responses. In
particular, genetic ablation of the ANP/GC-A or NO/sGC
systems in mice led to exacerbated cardiac hypertrophy in
response to pressure overload. Conversely, inhibition of
cGMP catabolism with the PDE5 inhibitor sildenafil pre-
vented and even reversed pathological cardiac hypertro-
phy after aortic banding [1].
The present ongoing study was originally designed to elu-
cidate whether the antihypertrophic effects of PDE5 inhi-
bition are linked to the formation of cGMP by either the
NP/GC-A or the NO/sGC system.
Methods
We subjected male C57Bl/6 mice (8 weeks of age, Charles
River) to constriction of the transverse aorta (TAC) for 4
weeks. They were concurrently treated with the PDE5
inhibitor sildenafil (100 mg/kg/d) or vehicle mixed in
solid food (n = 7 per group). Heart function was exam-
ined by Echocardiography before and at 2 and 4 weeks of
TAC. Thereafter, mice were anesthetized with 2% isoflu-
rane, and the extent of pressure overload was measured
via a right carotid artery PE-50 catheter connected to a
Statham pressure transducer. The animals (TAC vs. sham)
were then sacrificed and the lungs, hearts and individual
heart chambers were weighed (PW, HW, LVW). Tissue
weights were related to body weight (BW) and tibia length
(TL).
Results
In both groups of mice (sildenafil, placebo) 4 weeks of
TAC induced significant cardiac, i.e. left ventricular
enlargement, as indicated by the necropsy data (TAC vs
sham). After 4 weeks of banding, the systolic blood pres-
sure (proximal to the constriction) was lower in sildenafil-
treated (107 ± 6 mm Hg) than in placebo-treated mice
(126 ± 8 mm Hg). In spite of this, the average HW/BW
and LV/BW ratios were greater in sildenafil- than in pla-
cebo-treated banded mice (HW/BW: 7.3 ± 0.7 vs 6.4 ± 0.2;
LVW/BW: 5.8 ± 0.4 vs 5.1 ± 0.1, respectively). Also, pul-
monary wet weights were increased in the former (PW/
BW: 7.4 ± 1.4 vs. 5.6 ± 0.1). Similar data were obtained
after normalizing tissue weights to TL. Echocardiography
studies at 4 weeks of TAC demonstrated that ejection frac-
tions (EF) and fractional shortening (FS) on average were
lower in sildenafil- than in placebo-treated banded mice.
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Unexpectedly, in our ongoing study we could not observe
the cardiac protective effects of sildenafil which were pre-
viously published. On the opposite, PDE5 inhibition by
chronic sildenafil treatment seemed to increase the pro-
pensity to pressure overload – induced chamber dilata-
tion and cardiac failure. The mechanism(s) accounting for
this deleterious effect is presently unknown. Interestingly,
recent studies in isolated adult rat cardiomyocytes sug-
gested that PDE5 controls the soluble (sGC – derived) but
not the particulate (GC-A – dependent) cGMP pool,
whereas the latter is under the exclusive control of PDE2
[2]. The NO/sGC/cGMP system not only exerts antihyper-
trophic but also negative metabolic as well as inotropic
effects and opposes most of the positive effects of cAMP
on cardiac function [3,4]. Hence, our future studies will be
directed to elucidate whether an enhancement of the NO/
sGC/cGMP-signalling pathway by PDE5 inhibition under
certain stress conditions such as pressure overload, might
accelerate cardiac dysfunction.
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